ADME pharmacogenetics: current practices and future outlook

Bibliography

• Glavinas H, Krajcsi P, Cserepes J, Sarkadi B. The role of ABC transporters in drug resistance, metabolism and toxicity. Curr Drug Deliv 2004;1(1):27-42
   PubMedGoogle Scholar
• Pasanen MK, Neuvonen PJ, Niemi M. Global analysis of genetic variation in SLCO1B1. Pharmacogenomics 2008;9(1):19-33
   PubMed Web of Science ®Google Scholar
• Kirchheiner J, Brockmoller J. Clinical consequences of cytochrome P450 2C9 polymorphisms. Clin Pharmacol Ther 2005;77(1):1-16
   PubMed Web of Science ®Google Scholar
• Ingelman-Sundberg M. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J 2005;5(1):6-13
   PubMed Web of Science ®Google Scholar
• Hesselink DA, van Schaik RH, van der Heiden IP, et al. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin Pharmacol Ther 2003;74(3):245-54
   PubMed Web of Science ®Google Scholar
• Meyer UA, Zanger UM. Molecular mechanisms of genetic polymorphisms of drug metabolism. Annu Rev Pharmacol Toxicol 1997;37:269-96
   PubMed Web of Science ®Google Scholar
• Bromley CM, Close S, Cohen N, et al. Designing pharmacogenetic projects in industry: practical design perspectives from the Industry Pharmacogenomics Working Group. Pharmacogenomics J 2009;9(1):14-22
   PubMed Web of Science ®Google Scholar
• McCarthy MI, Abecasis GR, Cardon LR, et al. Genome-wide association studies for complex traits: consensus, uncertainty and challenges. Nat Rev Genet 2008;9(5):356-69
   PubMed Web of Science ®Google Scholar
• Grossman I, Goldstein DB. Translational genomics – Principles Pharmaogenetics/Pharmacogenomics. In: Willard HF, Ginsburg GS, editors, Essentials in genomics and personalized medicine: Academic Press/Elsevier, 2009 In Press
   Google Scholar
• Storey RF. Biology and pharmacology of the platelet P2Y12 receptor. Curr Pharm Des 2006;12(10):1255-9
   PubMed Web of Science ®Google Scholar
• Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction–summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients With Unstable Angina). J Am Coll Cardiol 2002;40(7):1366-74
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Contribution of gene sequence variations of the hepatic cytochrome P450 3A4 enzyme to variability in individual responsiveness to clopidogrel. Arterioscler Thromb Vasc Biol 2006;26(8):1895-900
   PubMed Web of Science ®Google Scholar
• Suh JW, Koo BK, Zhang SY, et al. Increased risk of atherothrombotic events associated with cytochrome P450 3A5 polymorphism in patients taking clopidogrel. CMAJ 2006 [Epub ahead of print]
   PubMedGoogle Scholar
• Brandt JT, Close SL, Iturria SJ, et al. Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. J Thromb Haemost 2007;5(12):2429-36
   PubMed Web of Science ®Google Scholar
• Kim KA, Park PW, Hong SJ, Park JY. The effect of CYP2C19 polymorphism on the pharmacokinetics and pharmacodynamics of clopidogrel: a possible mechanism for clopidogrel resistance. Clin Pharmacol Ther 2008;84(2):236-42
   PubMed Web of Science ®Google Scholar
• Hulot JS, Bura A, Villard E, et al. Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood 2006;108(7):2244-7
   PubMed Web of Science ®Google Scholar
• Geisler T, Schaeffeler E, Dippon J, et al. CYP2C19 and nongenetic factors predict poor responsiveness to clopidogrel loading dose after coronary stent implantation. Pharmacogenomics 2008;9(9):1251-9
   PubMed Web of Science ®Google Scholar
• Frere C, Cuisset T, Morange PE, et al. Effect of cytochrome p450 polymorphisms on platelet reactivity after treatment with clopidogrel in acute coronary syndrome. Am J Cardiol 2008;101(8):1088-93
   PubMed Web of Science ®Google Scholar
• Trenk D, Hochholzer W, Fromm MF, et al. Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents. J Am Coll Cardiol 2008;51(20):1925-34
   PubMed Web of Science ®Google Scholar
• Fontana P, Senouf D, Mach F. Biological effect of increased maintenance dose of clopidogrel in cardiovascular outpatients and influence of the cytochrome P450 2C19*2 allele on clopidogrel responsiveness. Thromb Res 2008;121(4):463-8
   PubMed Web of Science ®Google Scholar
• Collet JP, Hulot JS, Pena A, et al. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet 2009;373(9660):309-17
   PubMed Web of Science ®Google Scholar
• Simon T, Verstuyft C, Mary-Krause M, et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 2009;360(4):363-73
   PubMed Web of Science ®Google Scholar
• Mega JL, Close SL, Wiviott SD, et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 2009;360(4):354-62
   PubMed Web of Science ®Google Scholar
• Storey RF. Clopidogrel in acute coronary syndrome: to genotype or not? Lancet 2009;373(9660):276-8
   PubMed Web of Science ®Google Scholar
• Sugidachi A, Ogawa T, Kurihara A, et al. The greater in vivo antiplatelet effects of prasugrel as compared to clopidogrel reflect more efficient generation of its active metabolite with similar antiplatelet activity to that of clopidogrel's active metabolite. J Thromb Haemost 2007;5(7):1545-51
   PubMed Web of Science ®Google Scholar
• FDA. Table of valid genomic biomarkers in the context of approved drug labels. Available from: http://www.fda.gov/cder/genomics/genomic_biomarkers_table.htm [Last accessed 11 January 2009]
   Google Scholar
• US department of health and human services F. FDA Guidance for industry: pharmacogenomic data submissions; 2005
   Google Scholar
• Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353(12):1209-23
   PubMed Web of Science ®Google Scholar
• Grossman I, Sullivan PF, Walley N, et al. Genetic determinants of variable metabolism have little impact on the clinical use of leading antipsychotics in the CATIE study. Genet Med 2008;10(10):720-9
   PubMed Web of Science ®Google Scholar
• Sim SC, Ingelman-Sundberg M. The human cytochrome P450 Allele Nomenclature Committee Web site: submission criteria, procedures, and objectives. Methods Mol Biol 2006;320:183-91
   PubMedGoogle Scholar
• Miller DD, McEvoy JP, Davis SM, et al. Clinical correlates of tardive dyskinesia in schizophrenia: baseline data from the CATIE schizophrenia trial. Schizophr Res 2005;80(1):33-43
   PubMed Web of Science ®Google Scholar
• Patsopoulos NA, Ntzani EE, Zintzaras E, Ioannidis JP. CYP2D6 polymorphisms and the risk of tardive dyskinesia in schizophrenia: a meta-analysis. Pharmacogenet Genomics 2005;15(3):151-8
   PubMed Web of Science ®Google Scholar
• Ozdemir V, Kalow W, Posner P, et al. CYP1A2 activity as measured by a caffeine test predicts clozapine and active metabolite steady-state concentrationin patients with schizophrenia. J Clin Psychopharmacol 2001;21(4):398-407
   PubMed Web of Science ®Google Scholar
• Schulze TG, Schumacher J, Muller DJ, et al. Lack of association between a functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene and tardive dyskinesia in schizophrenia. Am J Med Genet 2001;105(6):498-501
   PubMed Web of Science ®Google Scholar
• Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Royal Stat Soc 1995;Series B(57):289-300
   Google Scholar
• Stroup TS, McEvoy JP, Swartz MS, et al. The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development. Schizophr Bull 2003;29(1):15-31
   PubMed Web of Science ®Google Scholar
• Hotopf M, Churchill R, Lewis G. Pragmatic randomised controlled trials in psychiatry. Br J Psychiatry 1999;175:217-23
   PubMed Web of Science ®Google Scholar
• MacGillivray S, Arroll B, Hatcher S, et al. Efficacy and tolerability of selective serotonin reuptake inhibitors compared with tricyclic antidepressants in depression treated in primary care: systematic review and meta-analysis. BMJ 2003;326(7397):1014
   PubMed Web of Science ®Google Scholar
• Song F, Freemantle N, Sheldon TA, et al. Selective serotonin reuptake inhibitors: meta-analysis of efficacy and acceptability. BMJ 1993;306(6879):683-7
   PubMed Web of Science ®Google Scholar
• Matchar DB, Thakur ME, Grossman I, et al. Testing for cytochrome P450 polymorphisms in adults with non-psychotic depression treated with selective serotonin reuptake inhibitors (SSRIs). Evid Rep Technol Assess 2007;(146):1-77
   PubMedGoogle Scholar
• Ando Y, Saka H, Ando M, et al. Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res 2000;60(24):6921-6
   PubMed Web of Science ®Google Scholar
• O'Dwyer PJ, Catalano RB. Uridine diphosphate glucuronosyltransferase (UGT) 1A1 and irinotecan: practical pharmacogenomics arrives in cancer therapy. J Clin Oncol 2006;24(28):4534-8
   PubMed Web of Science ®Google Scholar
• Palomaki GE, Bradley LA, Douglas MP, et al. Can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan? An evidence-based review. Genet Med 2009;11(1):21-34
   PubMed Web of Science ®Google Scholar
• Hoskins JM, Goldberg RM, Qu P, et al. UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters. J Natl Cancer Inst 2007;99(17):1290-5
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. Drug-Diagnostic co-development concept paper (draft – not for implementation); 2005
   Google Scholar
• Hinman L, Spear B, Tsuchihashi Z, et al. Drug-diagnostic codevelopment strategies: FDA and industry dialog at the 4th FDA/DIA/PhRMA/PWG/BIO Pharmacogenomics Workshop. Pharmacogenomics 2009;10(1):127-36
   PubMed Web of Science ®Google Scholar
• Simon R. The use of genomics in clinical trial design. Clin Cancer Res 2008;14(19):5984-93
   PubMed Web of Science ®Google Scholar
• Gulseth MP, Grice GR, Dager WE. Pharmacogenomics of warfarin: uncovering a piece of the warfarin mystery. Am J Health Syst Pharm 2009;66(2):123-33
   PubMed Web of Science ®Google Scholar
• Teagarden JR, Mayor T. Medco-Mayo warfarin study. Americam Health Information Community, Personalized health-care workshop; 2008 April; web-conference; 2008
   Google Scholar
• Williams JA, Andersson T, Andersson TB, et al. PhRMA white paper on ADME pharmacogenomics. J Clin Pharmacol 2008;48(7):849-89
   PubMed Web of Science ®Google Scholar
• Myrand SP, Sekiguchi K, Man MZ, et al. Pharmacokinetics/genotype associations for major cytochrome P450 enzymes in native and first- and third-generation Japanese populations: comparison with Korean, Chinese, and Caucasian populations. Clin Pharmacol Ther 2008;84(3):347-61
   PubMed Web of Science ®Google Scholar
• Available from: http://pharmaadme.org/joomla/
   Google Scholar
• Gaedigk A, Simon SD, Pearce RE, et al. The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype. Clin Pharmacol Ther 2008;83(2):234-42
   PubMed Web of Science ®Google Scholar
• McClain MR, Palomaki GE, Piper M, Haddow JE. A rapid-ACCE review of CYP2C9 and VKORC1 alleles testing to inform warfarin dosing in adults at elevated risk for thrombotic events to avoid serious bleeding. Genet Med 2008;10(2):89-98
   PubMed Web of Science ®Google Scholar
• Laje G, Paddock S, Manji H, et al. Genetic markers of suicidal ideation emerging during citalopram treatment of major depression. Am J Psychiatry 2007;164(10):1530-8
   PubMed Web of Science ®Google Scholar
• Sachse C, Brockmoller J, Bauer S, Roots I. Functional significance of a C–>A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine. Br J Clin Pharmacol 1999;47(4):445-9
   PubMed Web of Science ®Google Scholar
• Cornelis MC, El-Sohemy A, Campos H. Genetic polymorphism of the adenosine A2A receptor is associated with habitual caffeine consumption. Am J Clin Nutr 2007;86(1):240-4
   PubMed Web of Science ®Google Scholar
• Katz DA, Murray B, Bhathena A, Sahelijo L. Defining drug disposition determinants: a pharmacogenetic-pharmacokinetic strategy. Nat Rev Drug Discov 2008;7(4):293-305
   PubMed Web of Science ®Google Scholar
• Shen H, He MM, Liu H, et al. Comparative metabolic capabilities and inhibitory profiles of CYP2D6.1, CYP2D6.10, and CYP2D6.17. Drug Metab Dispos 2007;35(8):1292-300
   PubMed Web of Science ®Google Scholar
• Didziapetris R, Japertas P, Avdeef A, Petrauskas A. Classification analysis of P-glycoprotein substrate specificity. J Drug Target 2003;11(7):391-406
   PubMed Web of Science ®Google Scholar
• Uhr M, Tontsch A, Namendorf C, et al. Polymorphisms in the drug transporter gene ABCB1 predict antidepressant treatment response in depression. Neuron 2008;24:57(2):203-9
   Google Scholar
• Zhou SF. Structure, function and regulation of P-glycoprotein and its clinical relevance in drug disposition. Xenobiotica 2008;38(7-8):802-32
   PubMed Web of Science ®Google Scholar
• Dorado P, Penas-Lledo EM, Gonzalez AP, et al. Increased risk for major depression associated with the short allele of the serotonin transporter promoter region (5-HTTLPR-S) and the CYP2C9*3 allele. Fundam Clin Pharmacol 2007;21(4):451-3
   PubMed Web of Science ®Google Scholar
• Miksys S, Tyndale RF. Nicotine induces brain CYP enzymes: relevance to Parkinson's disease. J Neural Transm Suppl 2006;(70):177-80
   PubMed Web of Science ®Google Scholar
• Miksys S, Tyndale RF. Brain drug-metabolizing cytochrome P450 enzymes are active in vivo, demonstrated by mechanism-based enzyme inhibition. Neuropsychopharmacology 2009;34(3):634-40
   PubMed Web of Science ®Google Scholar
• Hesse LM, He P, Krishnaswamy S, et al. Pharmacogenetic determinants of interindividual variability in bupropion hydroxylation by cytochrome P450 2B6 in human liver microsomes. Pharmacogenetics 2004;14(4):225-38
   PubMedGoogle Scholar
• Lysakowski C, Dumont L, Czarnetzki C, et al. The effect of cigarette smoking on the hypnotic efficacy of propofol. Anaesthesia 2006;61(9):826-31
   PubMed Web of Science ®Google Scholar
• Chimbira W, Sweeney BP. The effect of smoking on postoperative nausea and vomiting. Anaesthesia 2000;55(6):540-4
   PubMed Web of Science ®Google Scholar
• Singer C, Grossman I, Avidan N, et al. Trick or treat: the effect of placebo on the power of pharmacogenetic association studies. Hum Genomics 2005;2(1):28-38
   PubMedGoogle Scholar
• Rehmel JL, Eckstein JA, Farid NA, et al. Interactions of two major metabolites of prasugrel, a thienopyridine antiplatelet agent, with the cytochromes P450. Drug Metab Dispos 2006;34(4):600-7
   PubMed Web of Science ®Google Scholar
• Caplain H, Donat F, Gaud C, Necciari J. Pharmacokinetics of clopidogrel. Semin Thromb Hemost 1999;25(Suppl 2):25-8
   PubMed Web of Science ®Google Scholar
• Pereillo JM, Maftouh M, Andrieu A, et al. Structure and stereochemistry of the active metabolite of clopidogrel. Drug Metab Dispos 2002;30(11):1288-95
   PubMed Web of Science ®Google Scholar
• Savi P, Pereillo JM, Uzabiaga MF, et al. Identification and biological activity of the active metabolite of clopidogrel. Thromb Haemost 2000;84(5):891-6
   PubMed Web of Science ®Google Scholar
• DMET™ Plus Premier Pack, Affymetrix, Inc. (Santa Clara, USA) Available from: http://www.affymetrix.com/products_services/arrays/specific/dmet.affx.
   Google Scholar